AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 162 min read$JNJ

Johnson & Johnson Announces CHMP Recommendation For Approval Of TALVEY Plus Daratumumab In Earlier Line Treatment Of Relapsed/Refractory Multiple Myeloma

Johnson & Johnson reported that the CHMP recommended approval for TALVEY (talquetamab) plus daratumumab for relapsed/refractory multiple myeloma. The MonumenTAL-3 study showed significant improvements in progression-free and overall survival for talquetamab combinations compared to standard treatment. Key secondary endpoints also showed statistically significant improvements, with manageable safety profiles.

Original reporting
marketscreener.com
Published Oct 16, 2026, 7:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 7:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The CHMP recommendation signals a likely EMA approval, expanding JNJ's oncology portfolio and supporting its share price.

02

Market read

First‑report regulatory endorsement for a high‑impact myeloma therapy, potentially moving JNJ stock and related biotech peers.

03

What to watch

Reimbursement negotiations and competition from BCMA‑targeted therapies may limit commercial upside.

Relevance 7/10Novelty 8/10Timing: today

Background

Johnson & Johnson's talquetamab (TALVEY) is a bispecific antibody targeting GPRC5D, a novel myeloma antigen.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

CHMP recommendation for approval of talquetamab plus daratumumab in earlier line RRMM treatment.

Expected impact

likely upward pressure as market prices in potential sales growth.

Evidence & confidence

First‑report of EMA CHMP recommendation; trial data show strong PFS and OS benefits, suggesting future label expansion.

Market effects

Sector

Strengthens the multiple myeloma therapeutic segment and may lift peer biotech stocks with similar targets.

Regional

European biotech sector could see modest gains from EMA endorsement.

Global

Adds to global oncology pipeline momentum, potentially influencing investor sentiment across pharma.

Counterpoint

What could challenge this read

If regulatory approval stalls or post‑approval safety issues emerge, the initial rally could reverse.

Key entities

  • company
    Johnson & Johnson

    US‑listed pharmaceutical giant developing talquetamab.

  • regulatory_body
    European Medicines Agency (EMA)

    Provides the CHMP recommendation for drug approvals in Europe.

Read at source← All news

StoryCHMP Recommends Earlier-Line TALVEY Combination for Relapsed Multiple Myeloma

Also covered by

2 outlets

Related articles

OCT 16
$JNJMed

Talquetamab Plus Daratumumab Earns CHMP Backing in R/R Myeloma

The EMA's CHMP recommended expanding talquetamab (Talvey) to include its use with daratumumab (Darzalex) in relapsed/refractory multiple myeloma. The phase 3 MonumenTAL-3 trial showed a 72% risk reduction in progression or death for talquetamab plus daratumumab and pomalidomide (Tal-DP) vs standard therapy. Johnson & Johnson's Ester in 't Groen highlighted significant improvements in PFS and OS, according to the company.

onclive.com7 min
OCT 16
$LLYHigh

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

tradingview.com2 min
OCT 16
$JNJMed

J&J Says CHMP Recommends Approval Of TALVEY Combo In Earlier Line Treatment Of R/R Multiple Myeloma

J&J EMEA announced the CHMP recommended approving TALVEY (talquetamab) in combination with daratumumab for treating adults with relapsed or refractory multiple myeloma who have had at least one prior therapy. The recommendation is based on Phase 3 results showing 81% progression-free survival and 89% overall survival at 24 months. If approved, it would be the only GPRC5D-targeting bispecific antibody combination therapy for second-line treatment.

rttnews.com1 min
OCT 15
$JNJLow

JNJ Maintains Rating by Morgan Stanley -- Price Target Lowered t

Morgan Stanley maintained its 'Overweight' rating for Johnson & Johnson (JNJ) but lowered its price target from $294.00 to $292.00. GuruFocus values JNJ at $194.40, suggesting a 31.7% overvaluation. The company has a GF Score™ of 83/100, with strong profitability and growth but weaker momentum. Insiders have sold $67.8M in shares over the last three months.

gurufocus.com1 min
OCT 15
$JNJMedAI 8/10

Johnson & Johnson outlook: bull and bear cases after Q3 earnings

Johnson & Johnson (JNJ) reported Q3 adjusted EPS of $2.59, beating estimates. The company raised operational sales-growth guidance to 6.7%–7.1% and maintained $21B in free cash flow. Bulls highlight pipeline momentum and technical support, while bears point to margin compression and MedTech weakness. The stock trades at $259.80, with analysts' target upside at 9.8%.

investing.com2 min